|Videos|July 14, 2015
ANNEXA-R Study Shows Promise for Rivaroxaban Reversal Agent
Advertisement
Episodes in this series
The results of the ANNEXA-R trial that sought to determine whether andexanet alfa could reverse the effects of rivaroxaban are promising, says Yekaterina Opsha, PharmD, BCPS-AQ Cardiology, a clinical specialist of cardiovascular medicine at Saint Barnabas Medical Center.
The double-blind, randomized, placebo-controlled trial examined 40 healthy patients divided in a 2:1 ratio between the active drug and placebo. The researchers found andexanet alfa served as a complete reversal agent for rivaroxaban, and the results were statistically significant.
“With this drug potentially coming out on the market, physicians might be a little more comfortable prescribing some of the novel oral anticoagulants,” Dr. Opsha says.
Advertisement
Related to this article
Authors of a pharmacist-directed transitions of care study discuss what drives pneumococcal vaccine hesitancy and how pharmacists can build systematic vaccine screening into inpatient workflows.
An investigational glypican-3–directed CAR T-cell therapy engineered to express IL-15 and IL-21 produced a complete response lasting at least 1 year in a child with chemotherapy-resistant metastatic hepatoblastoma.
The investigational once-weekly dual GLP-1/GIP receptor agonist, engineered with signaling bias at both receptors, met both primary end points at 48 weeks.
Investigational antiamyloid monoclonal antibodies may offer a novel pathway to disease reversal.
Increasingly, pharmacists are leading the obesity management team.
HYPERION trial data now support sotatercept within a patient's first year of pulmonary arterial hypertension (PAH) diagnosis, cutting clinical worsening risk by 76% compared with placebo.
A stewardship program combining EHR alerts and pharmacist-led education offers a replicable model for reducing bleeding risk.
A panel of cardiology pharmacists discussed the diagnostic red flags, evolving treatment landscape, and expanding pharmacist role central to identifying and managing ATTR-CM.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Bridging the Gap: Pharmacist Experiences Obtaining DEA Licenses
2
Armored CAR T-Cell Therapy Produces Durable Complete Response in Pediatric Solid Tumors
3
Expert Q&A: Pharmacists Address Pneumococcal Vaccine Hesitancy and Screening Complexity in Transitions of Care
4
Not So Rare After All: Pharmacists Weigh In on Diagnosing and Managing ATTR-CM
5